Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase III NETTER-1 study.

The study, which investigated the use of 177-Lu-Dotatate (Lutathera) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (NETs), met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in progression-free survival for 177-Lu-Dotatate versus a double dose of octreotide (Sandostatin LAR). 

There are not many options for patients with neuroendocrine tumors, so these results are exciting, says Ruszniewski.

View more from the 2015 European Cancer Congress

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

European Cancer Congress

Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.

Dr. Philippe Ruszniewski on NETTER-1 Study Results